Device Lobby AdvaMed Hires BIO Exec as New Leader

Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.

By Michael D. Williamson

Feb. 19 — The merry-go-round of health-care association leadership continues, as Scott Whitaker, an executive with a biotech lobby group, was named the new president and CEO of the Advanced Medical Technology Association, a device industry group.

Whitaker was the Biotechnology Innovation Organization's chief operating officer. He'll start his new position at AdvaMed April 4.

He takes over for Stephen Ubl, who left the device group last fall to be the head of the pharmaceutical trade group Pharmaceutical Research and Manufacturers of America (13 PLIR 1429, 10/2/15).

Whitaker also served in leadership roles at the Department of Health and Human Services, including as chief of staff and assistant secretary for legislation.

AdvaMed's Board of Directors announced Whitaker's appointment in a Feb. 18 statement.

“It is a tremendous privilege to join AdvaMed and represent such an innovative and life changing industry,” Whitaker said in the statement. “Given the many health care challenges throughout the world, it is critical that we work together to create a policy and regulatory environment that will allow this industry to continue to discover, develop and deliver innovative medical technologies to patients.”

AdvaMed Board Chairman Vincent A. Forlenza, chairman, CEO and president of the device firm BD, said in the release, “We are very pleased that Scott has agreed to lead AdvaMed at a time of unprecedented change in health care.”

Medical technology companies are at the forefront of developing solutions that improve patient outcomes and enable the delivery of high-quality, cost-effective care, Forlenza said. Continued progress in these areas depends on ensuring a strong innovation ecosystem and “Scott has a proven track record as an association leader, and we believe he has the vision to set the course for AdvaMed's future,” he said.

11 Years at BIO

In a separate Feb. 18 statement, Jim Greenwood, president and chief executive officer at BIO, praised Whitaker's tenure at the group. “During his 11-plus years at BIO, Scott has provided our organization with strong, steady, collegial and creative leadership,” Greenwood said.

Greenwood added that Whitaker “has been a trusted advisor throughout my tenure” and while he will be missed, part of his legacy will be the deep bench of talent he helped to build and cultivate at every level of BIO.

To contact the reporter on this story: Michael D. Williamson in Washington at

To contact the editor responsible for this story: Brian Broderick at

Request Health Care on Bloomberg Law